The data underlying Figs 2 and S4.

(A) Absence of cytotoxicity by the applied concentrations of the inhibitors of sphingolipid metabolic enzymes. Host cell viability based on resorufin fluorescence measured after 25.5 hrs of treatment with the indicated inhibitors. Data are displayed in S4A Fig. (B–C) Selected inhibitors of sphingolipid metabolic enzymes protected cells against cpoS mutant-induced cell death. Host cell viability based on resorufin fluorescence (B) and nuclei count (C) measured 25.5 hrs post infection and treatment with the indicated bacterial strains and inhibitors. Data are displayed in S4B Fig (B) and S4C Fig (C). (D–E) Selected inhibitors of sphingolipid metabolic enzymes protected cells against cpoS mutant-induced cell death and complementation of the mutant restored wild-type phenotypes. Host cell viability based on resorufin fluorescence (D) and nuclei count (E) measured 25.5 hrs post infection and treatment with the indicated bacterial strains and inhibitors. Data are displayed in Fig 2B (D) and Fig 2C (E). (F–G) Depletion of SPTLC1 or deficiency in KDSR protected cells against cpoS mutant-induced cell death. Host cell viability based on resorufin fluorescence (F) and nuclei count (G) measured 25.5 hrs post infection of the indicated cell lines with the indicated bacterial strains. Data are displayed in Fig 2F (F) and Fig 2G (G). (XLSX)